GSK is set to receive up to $500 million and 1% royalties on future vaccine sales following the settlement of a US patent dispute between CureVac NV, Pfizer, and BioNTech SE.

The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer ...

US Health Secretary Robert F. Kennedy Jr. has slashed government spending on mRNA vaccine research. Experts warn it will boost global vulnerability to future pandemics.

The rapid rise of the SARS-CoV-2 variant XFG this summer could make it the dominant strain by the start of the fall COVID season, but experts say current vaccines can likely handle the Omicron-based ...

A research project at Emory University is among the 22 grants and contracts that are being cancelled as the U.S. Department of Health and Human Services begins a “coordinated wind-down” of research ...

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

"Imagine defunding penicillin research in 1943 because of rare reactions. Absurd, right?" Dr. Jerome Adams wrote on X.

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The FTSE 100 edged down on Friday on a mixed day for European equities despite new optimism about an end to the war between ...

The pound rose to USD1.3450 late on Friday afternoon in London, compared to USD1.3412 at the equities close on Thursday. The euro traded at USD1.1666, higher against USD1.1631. Against the yen, the ...